Israeli Biotech Acquires Microbiome Company to Fight Chronic Liver Disease
BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets for chronic liver disease.
BiomX is a company based in Ness Ziona, Israel, developing customized phage therapy to selectively destroy the bacteria that cause diseases ranging from inflammatory bowel disease (IBD) to cancer. The company has just acquired RondinX, another Israeli biotech working in the microbiome space to strengthen its technology.
The technology BiomX has acquired from RondinX was developed by researchers at the Weizmann Institute of Science and MIT. Rather than analyzing static snapshots of gene expression in the microbiome at specific points in time, it makes use of metagenomic analysis to quantitatively predict the growth rate of specific bacterial strains. Using this method, the researchers were able to link high growth rates of pathogenic bacteria to the occurrence of conditions such as Crohn’s disease, type 2 diabetes and ulcerative colitis.
With the acquisition of RondinX, BiomX has also gained a new investor. San Francisco-based 8VC, which had previously invested in RondinX, decided to make a new investment in BiomX of an undisclosed amount. Earlier this year, BiomX raised $24M (€20M) in Series A. The company is now getting ready to take its first microbiome-targeting therapy, for IBD, to clinical studies in humans.
Image via BiomX